Cargando…

Novel Antischizophrenia Treatments

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with r...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Geyer, Mark A. (Editor ), Gross, Gerhard (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer, 2012.
Edición:1st ed. 2012.
Colección:Handbook of Experimental Pharmacology, 213
Temas:
Acceso en línea:Texto Completo

MARC

LEADER 00000nam a22000005i 4500
001 978-3-642-25758-2
003 DE-He213
005 20220115122833.0
007 cr nn 008mamaa
008 121009s2012 gw | s |||| 0|eng d
020 |a 9783642257582  |9 978-3-642-25758-2 
024 7 |a 10.1007/978-3-642-25758-2  |2 doi 
050 4 |a RM300-666 
072 7 |a MMG  |2 bicssc 
072 7 |a MED071000  |2 bisacsh 
072 7 |a MKG  |2 thema 
082 0 4 |a 615  |2 23 
245 1 0 |a Novel Antischizophrenia Treatments  |h [electronic resource] /  |c edited by Mark A. Geyer, Gerhard Gross. 
250 |a 1st ed. 2012. 
264 1 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg :  |b Imprint: Springer,  |c 2012. 
300 |a X, 458 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Handbook of Experimental Pharmacology,  |x 1865-0325 ;  |v 213 
505 0 |a Preface -- Clinical instruments to evaluate and guide treatment in schizophrenia -- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders -- Nicotinic mechanisms in psychotic disorders -- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia -- Inhibitors of glycine transport as potential new treatments in schizophrenia -- The role of glutamate in schizophrenia -- Metabotropic glutamate receptors as targets for new treatments in schizophrenia -- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions -- Phosphodiesterase inhibitors as potential new treatments in schizophrenia -- Disease modifying approaches to schizophrenia -- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia -- Transgenic animals reflecting aspects of schizophrenia -- Behavioral animal models of pro-cognitive treatments for schizophrenia. . 
520 |a This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications. 
650 0 |a Pharmacology. 
650 0 |a Pharmacy. 
650 0 |a Psychiatry. 
650 0 |a Psychobiology. 
650 1 4 |a Pharmacology. 
650 2 4 |a Pharmacy. 
650 2 4 |a Psychiatry. 
650 2 4 |a Biological Psychology. 
700 1 |a Geyer, Mark A.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Gross, Gerhard.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9783642257599 
776 0 8 |i Printed edition:  |z 9783642438097 
776 0 8 |i Printed edition:  |z 9783642257575 
830 0 |a Handbook of Experimental Pharmacology,  |x 1865-0325 ;  |v 213 
856 4 0 |u https://doi.uam.elogim.com/10.1007/978-3-642-25758-2  |z Texto Completo 
912 |a ZDB-2-SBL 
912 |a ZDB-2-SXB 
950 |a Biomedical and Life Sciences (SpringerNature-11642) 
950 |a Biomedical and Life Sciences (R0) (SpringerNature-43708)